Abstract: Membrane-bound voltage-gated Ca 2+ channels (VGCCs) are targets for specific signaling complexes, which regulate important processes like gene expression, neurotransmitter release and neuronal excitability. It is becoming increasingly evident that the so called "resistant" (R-type) VGCC Ca v 2.3 is critical in several physiologic and pathophysiologic processes in the central nervous system, vascular system and in endocrine systems. However its eponymous attribute of pharmacologic inertness initially made in depth investigation of the channel difficult. Although the identification of SNX-482 as a fairly specific inhibitor of Ca v 2.3 in the nanomolar range has enabled insights into the channels properties, availability of other pharmacologic modulators of Ca v 2.3 with different chemical, physical and biological properties are of great importance for future investigations. Therefore the literature was screened systematically for molecules that modulate Ca v 2.3 VGCCs.
The Ca v 2.3 Voltage-Gated Ca 2+ Channel
Ca v 2.3 belongs to the family of voltage-gated Ca 2+ channels which comprises ten different genes for ion conducting pore proteins ( Figure 1 ). The ion conducting pore protein of the Ca v 2.3 VGCCs was initially cloned from a rabbit brain cDNA library [1] . After functional expression of the rat Ca v 2.3 clone, it was initially speculated that it may represent the low voltage-activated T-type Ca 2+ channel, which was not yet structurally identified at that time [2] . However, consecutive cloning and expression of human Ca v 2.3 splice variants in X. laevis oocytes or HEK-293 cells revealed a VGCC with properties closer resembling a high-voltage-gated Ca 2+ channel [3, 4] . channels (modified according to [5] ). The cDNA of the putative membrane-spanning regions including the pore loops of the human sequences were aligned.
Although the structure of Ca v 2.3 deduced from sequencing of cDNA has now been known for several years [6, 7] , its physiological and pathophysiological roles are far from fully understood [8] [9] [10] . Evolutionarily, Ca v 2.3 may have developed very early [5, 11] , which may underline its great significance in vivo. The total quaternary structure of a Ca v 2.3-containing native VGCC is still unknown, but may contain additional subunits including the well known auxiliary -subunits, which have been shown to modulate Ca v 2.3-mediated inward currents in heterologous expression systems [12, 13] . Molecular properties of Ca v 2.3 have been characterized on the amino acid level for functional protein-protein interaction [14] [15] [16] however to date, Ca v 2. 3 VGCCs have yet to be purified as has been done for L-type Ca 2+ channels from rabbit skeletal muscle [17] [18] [19] [20] , and bovine heart [21] and for the neuronal N-type Ca 2+ channels [22, 23] . Sequence comparison of the deduced primary sequence revealed the well known intramolecular homology pattern, which is known for all voltage-gated Ca 2+ as well as for voltage-gated Na + channels. It contains four internal repeats, which have been termed domains I, II, III, and IV. Secondary structure analysis predicts 6 transmembrane segments including a random coiled short part between transmembrane segment 5 and 6, the pore forming segment (P-loop) [24] . Many of these structure predictions resemble the confirmed structural elements in the bacterial and rat voltage-gated K + -channel [25, 26] and a bacterial Na + -channel [27, 28] . Additional elements may contribute to the kinetic properties of Ca v 2.3-mediated inward currents as reported for structurally similar ion channels. The segments S6 participate in gating the ion channels [29] [30] [31] [32] , and the P-loops form essential parts of the selectivity filters, thereby also influencing the speed of the ion flux through the pore [33] [34] [35] [36] [37] [38] [39] [40] . The segment S4 acts mainly as the voltage sensor [41, 42] , and its detailed orientation to the pore region has been elucidated in crystals from the bacterial K + channel to a great extent [43] . 
Selective and Non-Selective Antagonists of Ca v 2.3
The first "pharmacoresistant" Ca 2+ current in vivo was recorded and published in 1993 [104, 105] , which means it occured between the years 1987 (the first cloning of a VGCC subunit [106] ) and 1994 (final cloning of the remaining high-voltage gated Ca 2+ channels). Doe-1, cloned from Discopyge ommata, represented a novel Ca 2+ channel type, which was insensitive towards dihydropyridines, but was antagonized rather than activated by 5 µM Bay K. This channel type was only slightly and readily reversibly inhibited by 5 µM -conotoxin-MVIIC, was insensitive towards -agatoxin-IVA, and fully reversibly blocked by -conotoxin-GVIA, an irreversible antagonist of N-type Ca 2+ channels [104] . Interestingly, the same group identified a similar Ca 2+ current component in rat cerebellar granule neurons and called the doe-1-like component "R-type current" [105] .
The peptide antagonist SNX-482, which was initially purified from the venom of the tarantula Hysterocratis gigas [107] [109] .
The first gene inactivation of Ca v 2.3 led to knock-out mice, which in cerebellar granule cells and in DRG neurons still expressed a drug insensitive Ba 2+ current. The peak inward current (I Ba ) was even larger than in cultured mouse neurons from contol mice (knock-out I Ba 113 ± 27 pA (n = 5 ); control 85 ± 21 pA (n = 9)) [110] . Only the wild type cultured neurons were inhibited by SNX-482, but not the neurons from Ca v 2.3-deficient mice, leading to the conclusion that a non-Ca v 2.3-dependent R-type current may exist.
In 113, 114] , notably also in neurodegenerative disease [115] . Table 3 
Physiological Functions, in Which Ca v 2.3 may be Involved, as Deduced from Ca v 2.3-Deficient Mice
Many of the experimental results from gene-inactivated mice cannot automatically transferred to human physiology and pathophysiology of human diseases. But some basic conclusions may be drawn from these investigations of Ca v 2.3-deficient mice, which were generated and analysed in several different laboratories (for detail, see Kamp et al.
Ca v 2.3 is expressed in many regions of the CNS and also in peripheral organs and tissues, which makes it difficult to explore its full function in vivo. Ca v 2.3 triggers or participates in the release of several neurotransmitters such as dopamine in the substantia nigra [117] . In the hippocampus Ca v 2.3 contributes to fast glutamatergic transmission [118] , where it is also involved in long term potentiation at the mossy fiber -CA3 synapses. Therefore, Ca v 2.3 participates in basic processes related to learning and memory formation [67, [119] [120] [121] . Furthermore, Ca v 2.3 is an important regulator in spines: activation of Ca v 2.3 triggers opening of small conductance Ca 2+ -activated K + -channels in CA1 hippocampal pyramidal neurons [122] [123] [124] , suggesting spine-restricted local microdomains, which are important for synaptic signalling [125] . R-type Ca 2+ currents, which were recorded as Ni 2+ -sensitive tail currents, are available at resting potential and contribute to after-depolarization, and thus to the initiation of burst firing in CA1 hippocampal neurons [126] . [150] .
Ca v 2.3-deficient mice reveal altered pain response [151] , and transcripts of two different splice variants of Ca v 2.3 could be identified in rat nociceptive neurons [152] . The major splice variant was Ca v 2.3e, which was also detected in the cerebellum, heart and endocrine system (Tables 1 and 2 
